SGMO News and Press, Sangamo Therapeutics Inc. From 05/08/25

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday...

All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. According to preliminary analysis, mean estimated glomerular filtration rate (eGFR) slope at 52-weeks continued to remain positive....

One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion disease in animal models Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine com...

2025-04-04 14:57:37 ET Summary Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with ...

2025-04-03 17:21:24 ET More on Eli Lilly, Sangamo Therapeutics Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors Eli Lilly: Growth With Higher Margins Sang...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payme...

2025-03-17 18:29:40 ET Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Conference Call March 17, 2025, 04:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Natha...

2025-03-17 16:07:01 ET More on Sangamo Therapeutics Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit Sangamo Therapeutics: Left At The Altar (Rating Downgrade) Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development Sangamo T...

Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop ...